Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer

Next Previous
X
Search
Trial Profile

Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 9496 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca

    • Most Recent Events

    • 10 Apr 2021 Results (n=12) by taking Individual CTC and ctDNA, assessing whether serial monitoring of CTC and ctDNA genomic alterations is feasible and should enable real-time tracking of response/progression in advanced breast cancer, presented at the 112th Annual Meeting of the American Association for Cancer Research
    • 21 Jun 2019 Status changed from active, no longer recruiting to completed.
    • 23 Jan 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top